poisar

Stocks · News reference

ImmunityBio Reports Q3 2026 Financial Results and Regulatory Milestones

Fiscal.ai

ImmunityBio announced its third-quarter 2026 financial results, reporting $48.7 million in net product revenue, alongside updates on global expansion and expanded FDA approvals.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaVandana Singh

    ImmunityBio Reports Wider Quarterly Loss

    ImmunityBio stock falls as Q3 revenue misses estimates, despite positive ANKTIVA bladder cancer trial results and Israeli approval.